Please click and read this disclaimer if you wish to continue with the contents below.
For my previous portfolio review click
here
YTD(2021) I have made a total profit of S$57,002.74 from my equity
investments(predominantly in HK) with an XIRR of 58.34%(XIRR is annualized).
From my 6 years of tracking, I have made a total of S$156,645.40 from
this portfolio alone.
Portfolio composition(2 index etfs and 29 stocks):
Transactions:
Initiated a 2.66% position in JD Health(HK:6618)
Sold all China Motor Bus(HK:0026) for 26.3% gain
Commentary:
JXR(HK:1951) saw a 17.51% price increase today(overall up 54.56% for me), as Politburo is
pondering on implementation and supporting measures for couples to have
three children. Everyone seems to be optimistic that the third child is a
positive for Chinese real estate. I think it’s short and long. Short term,
It's good because there is a replacement demand for three children.
Long term, the biggest factor suppressing fertility hospitals is high
housing prices. If you want to encourage fertility, the housing price issue
must be resolved.
From an investment perspective, good for maternity and infant industry
stocks, such as infant milk powder, toy, children's clothing, assisted
reproductive industry, the kindergarten industry. Goodbaby International is
currently up 30% too. Also need to take note of the market overpricing
this.
This policy has affected the whole healthcare segment, even my CMER Eye
Care(HK:3309) saw some positive activity today. See how it goes.
JD Health(HK:6618) is a telemedicine company cum pharmacy ecommerce.
I initiated a 2.66% position recently after its price dropped close to 50%
from its peak. JD Health direct competitor is Ali Health. Online
pharmacy so far has been more profitable than digital medical services, but
the suspension of outpatient services during the COVID-19 outbreak triggered
a big shift toward online consultation. JD Health is the largest among
the Chinese online healthcare services, with revenue nearly double that of
its closest competitors, Alibaba Health and PingAn GoodDoctor. In addition
to online pharmacy services, JD Health offers its own in-house doctors, a
network of external doctors and around-the-clock family doctor service.
Its core currently is still selling medicine(ecommerce) with a smaller
segment for telemedicine. JD has the best in house logistic and customer
service while Alibaba is outsourcing via Cainao and hence do not have the
same standard of customer service as JD. Alibaba is also well known for mismanaging their subsidiaries. Xiami and Youku are a few examples.
JD Health topline is growing faster than Ali Health and has a higher gross
margin. Both are trading similarly at ard 15x p/s. JD Health is the
undisputed leader currently. I am bullish on China's medical and health tech
sector.
APT Satellite(HK:1045) this deep value cash rich stock saw a 65% rise
since start of this year. Today its price went up another 7%. Likely due to
Chinese space station news
here. The technology prowess of China is breaking boundaries. In the past,
the Chinese are barred from the ISS and the Americans do not want to share
their space knowledge with them.
Now China created their own space station from scratch and even manage to
launch and land a rover onto Mars. Tiangong is China’s first permanent
space station and once completed, it is expected to be in operation for at
least 10 years, with the capacity to host three permanent residents and
three visitors. It will be joined in orbit by the Xuntian optical space
telescope. All instructions are in Chinese. The technology prowess of the
Chinese I feel, has the per capita brain power and money to surpass the
Americans if given time.
No comments :
Post a Comment